Estrada-Gómez R, Vargas-Castro O, Oropeza-Borges M, González-Carrillo ML, Pérez-Romano B, Ruiz-Argüelles GJ

Language: English
References: 7
Page: 424-427
PDF size: 44.13 Kb.

ABSTRACT

In a 20-year period in a single institution, 34 patients with chronic, refractory autoimmune thrombocytopenic purpura were prospectively treated with ex vivo anti-D opsonized autologous red blood cells. All patients had received previous treatment with steroids and/or immunosuppressive agents, and 11 had been splenectomized. Twenty one patients had an increase in the platelet count; in five cases, the increase was more than 50 x 10⁹/L platelets and in 16 the increase was more than 100 x 10⁹/L platelets. Early responses were observed in 20 patients and late responses in seven, whereas seven patients (20%) did not respond at all. Nine of the 20 individuals who achieved an ER had a subsequent drop in the platelet count; however, only three had a drop below 50 x 10⁹/L. When last censored, of the 34 patients, 24 (70%) had a platelet count above 50 x 10⁹/L. The 84-month thrombocytopenia-free (over 50 x 10⁹/L platelets) status of the whole group is 70%, whereas the 84-month complete remission (over 100 x 10⁹/L platelets) status of the whole group is 50%. It is concluded that the use of ex vivo anti-D opsonized red blood cells may represent another, substantially cheaper treatment of patients with chronic, refractory, autoimmune thrombocytopenic purpura.

REFERENCES

1. Jones HW, Tocantis LM. The history of purpura hemorrhagica. Ann Med Hist 1933; 5: 349-59.

2. Tarantino MD, Goldsmith. Treatment of autoimmune thrombocytopenic purpura. Sem Hematol 1998; 35(Suppl. 1): 28- 35.

3. Pizzuto-Chávez J, Gutiérrez-Espíndola G. Plaquetas y púrpuras trombocitopénicas. En: Ruiz-Argüelles GJ (ed.). Fundamentos de Hematología. 3a In México: Editorial Médica Panamericana; 1998, p. 377-97.

4. Ambriz R, Muñoz R, Pizzuto J, Quintanar E, Morales-Polanco M, Avilés A. Low dose autologous in vitro opsonized erythrocytes. Radioimmune method and autologous opsonized erythrocytes for refractory autoimmune thrombocytopenic purpura in adults. Arch Intern Med 1987; 147: 105-08.

5. Ruiz-Argüelles GJ, Apreza-Molina MG, Pérez-Romano B, Ruiz- Argüelles A. The infusion of anti-RhO-(D) opsonized erythrocytes may be useful in the treatment of patients, splenectomized or not, with chronic, refractory autoimmune thrombocytopenic purpura. A prospective study. Am J Hematol 1993; 43: 72-3.

6. Ruiz-Argüelles GJ, López-Martínez B, Flores-Martínez J, Ruiz- Argüelles A, Pérez-Romano B. An affordable Fc-receptor blockade method for the treatment of patients with chronic, refractory autoimmune thrombocytopenic purpura. Haematologica 2001; 86: 481-2.

7. Scaradavou A, Bussel JB. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. Sem Hematol 1998; 35(Suppl. 1): 52-7.